Publications

Peer-Reviewed Articles

2017

  1. Schelch K, Kirschner MB, Williams M, Cheng YY, van Zandwijk N, Grusch M, Reid G. A link between the FGF axis and the miR-16 family reveals potential new treatment combinations in Mesothelioma. Mol Oncol 2017: Accepted.
  2. Johnson TG, Schelch K, Cheng YY, Williams M, Sarun KH, Kirschner MB, Kao S, Linton A, Klebe S, McCaughan BC, Lin RCY, Pirker C, Berger W, Lasham A, van Zandwijk N, Reid G. Dysregulated expression of the microRNA miR-137 and its target YB‑1 contribute to the invasive characteristics of malignant pleural mesothelioma. J Thorac Oncol, 2017: Accepted.
  3. Cheng YY, Mok E, Tan S, Leygo C, George AM, Reid G. SFRP tumour suppressor genes are potential plasma-based epigenetic biomarkers for malignant pleural mesothelioma. Disease Markers: July 2017: Accepted
  4. Leygo C, Williams M, Jin HC, Chan MWY, Chu WK, Grusch M, Cheng YY. DNA methylation as a noninvasive epigenetic biomarker for the detection of cancer. Dis Markers. 2017;2017:3726595.  PMID: 29038612
  5. Furuya S, Takahashi K. Experience of Japan in achieving a total ban on asbestos. Int J Environ Res Public Health. 2017;14(10):1261. PMID: 29053631
  6. GBD_2016_Causes_of_Death_Collaborators, (Takahashi K, included). Global, regional, and national age-sex specific mortality for 264 causes of death, 1980-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet. 2017;390(10100):1151-210. PMID: 28919116
  7. Global_Burden_of_Disease_Cancer_Collaboration, (Takahashi K, included). Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 32 cancer groups, 1990 to 2015: a systematic analysis for the Global Burden of Disease Study. JAMA Oncol. 2017;3(4):524-48. PMID: 27918777
  8. Kresoja-Rakic J, Sulemani M, Kirschner MB, Ronner M, Reid G, Kao S, Schwaller B, Weder W, Stahel RA, Felley-Bosco E. Posttranscriptional regulation controls calretinin expression in malignant pleural mesothelioma. Front Genet. 2017 May 29;8:70. doi: 10.3389/fgene.2017.00070. eCollection 2017. PMID: 28611824
  9. van Zandwijk N, Pavlakis N, Kao SC, Linton A, Boyer MJ, Clarke S, Huynh Y, Chrzanowska A, Fulham MJ, Bailey DL, Cooper WA, Kritharides L, Ridley L, Pattison ST, MacDiarmid J, Brahmbhatt H, Reid G. Safety and activity of microRNA-loaded minicells in patients with recurrent malignant pleural mesothelioma: a first-in-man, phase 1, open-label, dose-escalation study. Lancet Oncol. 2017; http://dx.doi.org/10.1016/S1470-2045(17)30596-X PMID: 28870611
  10. Kao SC, Cheng YY, Williams M, Kirschner MB, Madore J, Lum T, Sarun KH, Linton A, McCaughan B, Klebe S, van Zandwijk N, Scolyer RA, Boyer MJ, Cooper WA, Reid G. Tumor suppressor microRNAs contribute to the regulation of PD-L1 expression in malignant pleural mesothelioma. J Thorac Oncol. 2017;12(9):1421-33. PMID: 28629895
  11. Sawanyawisuth K, Furuya S, Park EK, Myong JP, Ramos-Bonilla JP, Chimed Ochir O, Takahashi K. Compensation for asbestos-related diseases in Japan: utilization of standard classifications of industry and occupations. Asian Pac J Cancer Prev. 2017;18(7):1779-82. PMID: 28749105
  12. Odgerel C-O, Takahashi K, Sorahan T, Driscoll T, Fitzmaurice C, Yoko-o M, Sawanyawisuth K, Furuya S, Tanaka F, Horie S, van Zandwijk N, Takala J. Estimation of the global burden of mesothelioma deaths from incomplete national mortality data. Occup Environ Med. 2017; [Epub ahead of print]. PMID: 28866609
  13. Takala J, Hamalainen P, Nenonen N, Takahashi K, Chimed-Ochir O, Rantanen J. Comparative analysis of the burden of injury and illness at work in selected countries and regions. Cent Eur J Occup Environ Med. 2017;23(1-2):6-31.
  14. Robb T, Reid G, Blenkiron C. Exploiting microRNAs as cancer therapeutics. Target Oncol. 2017;12(2):163-78. PMID: 28138797
  15. Manegold C, Dingemans AC, Gray JE, Nakagawa K, Nicolson M, Peters S, Reck M, Wu YL, Brustugun OT, Crino L, Felip E, Fennell D, Garrido P, Huber RM, Marabelle A, Moniuszko M, Mornex F, Novello S, Papotti M, Perol M, Smit EF, Syrigos K, van Meerbeeck JP, van Zandwijk N, Chih-Hsin Yang J, Zhou C, Vokes E. The potential of combined immunotherapy and antiangiogenesis for the synergistic treatment of advanced NSCLC. J Thorac Oncol. 2017;12(2):194-207. PMID: 27729297
  16. Linton A, Soeberg M, Broome R, Kao S, van Zandwijk N. Geographic and socioeconomic factors in patients with malignant pleural mesothelioma in New South Wales and their impact upon clinical outcomes. Respirology. 2017;22(5):978-85. PMID: 28139858

2016

  1. Williams M, Cheng YY, Blenkiron C, Reid G. Exploring mechanisms of microRNA downregulation in cancer. MicroRNA. 2016 Dec 8. [Epub ahead of print] PMID: 27928946
  2. Soeberg MJ, Leigh J, van Zandwijk N. Malignant mesothelioma in Australia 2015: Current incidence and asbestos exposure trends. J Toxicol Environ Health B Crit Rev. 2016;19(5-6):173-89. PMID: 27705544
  3. Hoda MA, Dong Y, Rozsas A, Klikovits T, Laszlo V, Ghanim B, Stockhammer P, Ozsvar J, Jakopovic M, Samarzija M, Brcic L, Bendek M, Szirtes I, Reid G, Kirschner MB, Kao SC, Opitz I, Weder W, Frauenfelder T, Nguyen-Kim TD, Aigner C, Klepetko W, van Zandwijk N, Berger W, Dome B, Grusch M, Hegedus B. Circulating activin A is a novel prognostic biomarker in malignant pleural mesothelioma - A multi-institutional study. Eur J Cancer. 2016 Aug;63:64-73. PMID: 27288871
  4. Driml J, Pulford E, Moffat D, Karapetis C, Kao S, Griggs K, Henderson DW, Klebe S. Usefulness of Aquaporin 1 as a prognostic marker in a prospective cohort of malignant mesotheliomas. Int J Mol Sci. 2016 Jun;17(7), 1041. PMID: 27376267
  5. Bremnes RM, Busund LT, Kilvaer TL, Andersen S, Richardsen E, Paulsen EE, Hald S, Khanehkenari MR, Cooper WA, Kao SC, Donnem T. The role of tumor-infiltrating lymphocytes in development, progression, and prognosis of non-small cell lung cancer. J Thorac Oncol. 2016 Jun;11(6):789-800. PMID: 26845192
  6. Soeberg MJ, Creighton N, Currow DC, Young JM, van Zandwijk N. Patterns in the incidence, mortality and survival of malignant pleural and peritoneal mesothelioma, New South Wales, Australia, 1972-2009. Aust N Z J Public Health. 2016 Jun;40(3):255-62. PMID: 26713662
  7. Cheng YY, Wright CM, Kirschner MB, Williams M, Sarun KH, Sytnyk V, Leshchynska I, Edelman JJ, Vallely MP, McCaughan BC, Klebe S, van Zandwijk N, Lin RCY, Reid G.1, a calcium-activated potassium channel subunit alpha 1, is targeted by miR-17-5p and modulates cell migration in malignant pleural mesothelioma. Mol Cancer. 2016 Jun 1;15(1):44. PMID: 27245839
  8. Lin RCY, Kirschner MB, Cheng YY, van Zandwijk N, Reid G. MicroRNA gene expression signatures in long-surviving malignant pleural mesothelioma patients. Genom Data. 2016 9:44-9. Doi:10.1016/j.gdata.2016.06.009
  9. Reid G, Kao SC, Pavlakis N, Brahmbhatt H, MacDiarmid J, Clarke S, Boyer M, van Zandwijk N. Clinical development of TargomiRs, a miRNA mimic-based treatment for patients with recurrent thoracic cancer. Epigenomics. 2016;8(8):1079-85. PMID: 27185582
  10. Soeberg MJ, Luong MA, Tran VT, Tran AT, Nguyen TTH, Bui D, Nguyen THN, Takahashi K, van Zandwijk N. Estimating the incidence of malignant mesothelioma in Vietnam: a pilot descriptive cancer registration study. Int J Occup Environ Health. 2016 Apr;22(2):167-72. PMID: 27388204
  11. Kao SC, Boyer MJ. Evolving landscape of epidermal growth factor receptor tyrosine kinase inhibitors. J Clin Oncol. 2016;34(27):3233-4. PMID: 27069076
  12. Kao SC, Kirschner MB, Cooper WA, Tran T, Burgers S, Wright C, Korse T, van den Broek D, Edelman J, Vallely M, McCaughan B, Pavlakis N, Clarke S, Molloy MP, van Zandwijk N, Reid G. A proteomics-based approach identifies secreted protein acidic and rich in cysteine as a prognostic biomarker in malignant pleural mesothelioma. Br J Cancer. 2016 Mar 1;114(5):524-31. PMID: 26889976
  13. van Zandwijk N, Soeberg M, Reid G. Using a multidisciplinary approach to combat the burden of asbestos-related disease. Med J Aust. 2016 Feb 1;204(2) : 52. PMID: 26821095
  14. Soeberg M J, Leigh J, Driscoll T, Armstrong B, Young JM, van Zandwijk N. Incidence and survival trends in malignant pleural and peritoneal mesothelioma, Australia, 1982-2009. Occup Environ Med. 2016 Mar;73(3):187-94.  PMID: 26800709

2015

  1. Soeberg M, van Zandwijk N. Incidence of malignant mesothelioma in New Zealand and Australia – a global snapshot. [Letter] NZ Med J. 2015;128(1427):68-71. PMID: 26914008
  2. Glover AR, Zhao JT, Gill AJ, Weiss J, Mugridge N, Kim E, Feeney AL, Ip JC, Reid G, Clarke S, Soon PS, Robinson BG, Brahmbhatt H, MacDiarmid JA, Sidhu SB. microRNA-7 as a tumor suppressor and novel therapeutic for adrenocortical carcinoma. 2015 Nov 3;6(34):36675-88. PMID: 26452132
  3. Kirschner MB, Pulford E, Hoda MA, Rozsas A, Griggs K, Cheng YY, Edelman JJB, Kao SC, Hyland R, Dong Y, László V, Klikovits T, Vallely MP, Grusch M, Hegedus B, Dome B, Klepetko W, van Zandwijk N, Klebe S, Reid G. Fibulin-3 levels in malignant pleural mesothelioma are associated with prognosis but not diagnosis. Br J Cancer. 2015 Sep 15; 113(6): 963-9. PMID: 26263483
  4. Williams M, Kirschner MB, Cheng YY, Hanh J, Weiss J, Mugridge N, Wright CM, Linton A, Kao SC, Edelman JJB, Vallely MP, McCaughan BC, Cooper W, Klebe S, Lin RCY, Brahmbhatt H, MacDiarmid J, van Zandwijk N, Reid G. miR-193a-3p is a potential tumor suppressor in malignant pleural mesothelioma. Oncotarget. 2015 Sep 15; 6(27):23480-95. PMID: 26125439
  5. Kao SC, Fulham M, Wong K, Cooper W, Brahmbhatt H, MacDiarmid J, Pattison S, Sagong JO, Huynh Y, Leslie F, Pavlakis N, Clarke S, Boyer M, Reid G,  van Zandwijk N. A significant metabolic and radiological response after a novel targeted microRNA-based treatment approach in malignant pleural mesothelioma. [To the Editor] Am J Respir Crit Care Med. 2015;191(12):1467-1469.  PMID: 26075427
  6. Reid G. MicroRNAs in mesothelioma: from tumour suppressors and biomarkers to therapeutic targets. J Thorac Dis. 2015 Jun;7(6):1031-40. PMID: 26150916
  7. Cooper WA, Tran T, Vilain RE, Madore J, Selinger CI, Kohonen-Corish M, Yip P, Yu B, O'Toole SA, McCaughan BC, Yearley JH, Horvath LG, Kao S, Boyer M, Scolyer RA. PD-L1 expression is a favorable prognostic factor in early stage non-small cell carcinoma. Lung Cancer. 2015 Aug;89(2):181-8. PMID: 26024796
  8. Birnie KA, Yip YY, Ng DCH, Kirschner MB, Reid G, Prele CM, Musk AW, Lee YCG, Thompson PJ, Mutsaers SE, Badrian B. Loss of mir-223 and JNK signalling contribute to elevated Stathmin in malignant pleural mesothelioma. Mol Cancer Res. 2015 Jul;13(7):1106-18. PMID: 25824152
  9. Klebe S, Griggs K, Cheng Y, Driml J, Henderson DW, Reid G. Blockade of aquaporin 1 inhibits proliferation, motility, and metastatic potential of mesothelioma in vitro but not in an in vivo Dis Markers. 2015;2015:286719. PMID: 25821338
  10. Luk PP, Yu B, Ng CC, Mercorella B, Selinger C, Lum T, Kao S, O'Toole SA, Cooper WA. BRAF mutations in non-small cell lung cancer. Transl Lung Cancer Res. 2015 Apr;4(2):142-8. PMID: 25870796
  11. Kumarakulasinghe NB,van Zanwijk N, Soo RA. Molecular targeted therapy in the treatment of advanced stage non-small cell lung cancer (NSCLC). Fong KM, van Zanwijk N. (Series Ed.) Invited Review Series: Lung cancer practice, implementing evidence around the world.   2015 Apr;20(3):370-8.  PMID: 25689095
  12. van Zandwijk N, Fong KM. Update in lung cancer: Prologue to a modern review series. Fong KM, van Zandwijk N. (Series Ed.) Series Editorial – Prologue: Lung cancer practice, implementing evidence around the world. Respirology. 2015 Feb;20(2):183–4. PMID: 25594901
  13. Kao SC-H, van Zandwijk N, Clarke S, Vardy J, Lumba S, Tognela A, Ng W. Estimation of an optimal chemotherapy utilization rate for malignant pleural mesothelioma: An evidence-based benchmark for cancer care. Asia Pac J Clin Oncol. 2015 Mar;11(1): 85-92. PMID: 25382807
  14. Kirschner MB, Cheng YY, Armstrong NJ, Lin RCY, Kao SC, Linton A, Klebe S, McCaughan BC, van Zandwijk N, Reid G. MiR-Score: A novel 6-microRNA signature that predicts survival outcomes in patients with malignant pleural mesothelioma. Mol Oncol. 2015 Mar;9(3):715-26.  PMID: 25497279
  15. Lin RCY, van Zandwijk N, Reid G. MicroRNA therapeutics – back in vogue? Editorial. J Investig Genomics. 2015;2(1):00012.

2014

  1. Soeberg M, van Zandwijk N. The ticking time-bomb of asbestos consumption in the Asian region. Asia-Pac Newsl Occup Health Safety. 2014 Nov;21(2):24-7.
  2. Lin RCY, Ng S-F, Morris MJ. Gene expression in rat models for inter-generational transmission of islet dysfunction and obesity. Data in brief. Genom Data. 2014 Dec;2:351-3. PMID: 26484128
  3. Linton A, Pavlakis N, O'Connell R, Soeberg M, Kao S, Clarke S, Vardy J, van Zandwijk N. Factors associated with survival in a large series of patients with malignant pleural mesothelioma in New South Wales. Br J Cancer. 2014 Oct 28;111(9):1860-9. PMID: 25188323
  4. Kao SC-H, van Zandwijk N, Clarke S. Comment on ‘Existing prognostic models, but not neutrophil-to-lymphocyte ratio, are prognostic in malignant pleural mesothelioma’. Br J Cancer. 2014 Dec 9;111(12):2376. PMID: 24714747
  5. Cheng NC, van Zandwijk N, Reid G. Cilengitide inhibits attachment and invasion of malignant pleural mesothelioma cells through antagonism of integrins αvβ3 and αvβ PLoS One. 2014 Mar 3;9(3):e90374.  PMID: 24595274
  6. Linton A, Cheng YY, Griggs K, Kirschner MB, Gattani S, Srikaran S, Kao SC-H, McCaughan BC, Klebe S, van Zandwijk N, Reid G. An RNAi-based screen reveals PLK1, CDK1 and NDC80 as potential therapeutic targets in malignant pleural mesothelioma. Br J Cancer. 2014 Jan 21;110(2):510-9.  PMID: 24327015

2013

  1. Reid G, Pel ME, Kirschner MB, Cheng YY, Mugridge N, Weiss J, Williams M, Wright C, Edelman JJB, Vallely MP, McCaughan BC, Klebe S, Brahmbhatt H, MacDiarmid JA, van Zandwijk N. Restoring expression of miR-16: a novel approach to therapy for malignant pleural mesothelioma. Ann Oncol. 2013 Dec;24(12):3128–35. PMID: 24148817
  2. van Zandwijk N. Clinical practice guidelines for malignant pleural mesothelioma. J Thorac Dis. 2013 Dec;5(6):724-5. PMID: 24409346
  3. van Zandwijk N, Clarke C, Henderson D, Musk AW, Fong K, Nowak A, Loneragan R, McCaughan B, Boyer M, Feigen M, Currow D, Schofield P, Ivimey B, Pavlakis N, McLean J, Marshall H, Leong S, Keena V, Penman A. Guidelines for the diagnosis and treatment of malignant pleural mesothelioma. J Thorac Dis. 2013 Dec;5(6):E254-307. (Review) PMID: 24416529
  4. Majewski IJ, Mittempergher L, Davidson NM, Bosma A, Willems SM, Horlings HM, de Rink I, Greger L, Hooijer GKJ, Peters D, Nederlof PM, Hofland I, de Jong J, Wesseling J, Kluin RJC, Brugman W, Kerkhoven R, Nieboer F, Roepman P, Broeks A, Muley TR, Jassem J, Niklinski J, van Zandwijk N, Brazma A, Oshlack A, van den Heuvel M, Bernards R. Identification of recurrent FGFR3 fusion genes in lung cancer through kinome-centred RNA sequencing. J Pathol. 2013 Jul;230(3):270-6. PMID: 23661334
  5. Wright CM, Kirschner MB, van Zandwijk N, Reid G. Does miR-1 play a role in malignant pleural mesothelioma development and progression? Chest 2013 Dec;144 (6):1971. PMID: 24297134
  6. Cheng YY, Kirschner MB, Cheng NC, Gattani S, Klebe S, Edelman JJB, Vallely MP, McCaughan BC, Jin HC, van Zandwijk N, Reid G. ZIC1 is silenced and has tumour suppressor function in malignant pleural mesothelioma. J Thorac Oncol. 2013 Oct; 8(10):1317-28.  PMID: 24457242
  7. Honeyball F, Boyer M, van Zandwijk N, Kao SC. Malignant pleural mesothelioma. CancerForum. 2013;37(2). Available from: http://cancerforum.org.au/forum/2013/july/malignant-pleural-mesothelioma/
  8. Wright CM, Kirschner MB, Cheng YY, O’Byrne KJ, Gray SG, Schelch K, Hoda MA, Klebe S, McCaughan B, van Zandwijk N, Reid G. Long non coding RNAs (lncRNAs) are dysregulated in malignant pleural mesothelioma (MPM). PLoS One. 2013 Aug 19;8(8):e70940. PMID: 23976967
  9. Lim CB, Prêle CM, Cheah HM, Cheng YY, Klebe S, Reid G, Watkins DN, Baltic S, Thompson PJ, Mutsaers SE. Mutational analysis of Hedgehog signaling pathway genes in human malignant mesothelioma. PLoS One. 2013 Jun 24;8(6):e66685. PMID: 23826113
  10. Henderson DW, Reid G, Kao SC, van Zandwijk N, Klebe S. Challenges and controversies in the diagnosis of mesothelioma: Part 1. Cytology-only diagnosis, biopsies, immunohistochemistry, discrimination between mesothelioma and reactive mesothelial hyperplasia, and biomarkers. J Clin Pathol. 2013 Oct;66(10):847-53. PMID: 23814259
  11. Henderson DW, Reid G, Kao SC, van Zandwijk N, Klebe S. Challenges and controversies in the diagnosis of malignant mesothelioma: Part 2: Malignant mesothelioma subtypes, pleural synovial sarcoma, molecular and prognostic aspects of mesothelioma, BAP1, aquaporin-1and microRNA. J Clin Pathol. 2013 Oct;66(10):854-61. PMID: 23833051
  12. Kirschner MB, Edelman JJB, Kao SC-H, Vallely MP, Van Zandwijk N, Reid G. The impact of hemolysis on cell-free microRNA biomarkers. Front Genet. 2013 May 24; 4:94. PMID: 23745127
  13. Kirschner MB, van Zandwijk N, Reid G. Cell-free microRNAs: potential biomarkers in need of standardized reporting. Front Genet. 2013 April 19; 4:56.  PMID: 23626598
  14. Kao SC, van Zandwijk N, Corte P, Clarke C, Clarke S, Vardy J. Use of cancer therapy at the end of life in patients with malignant pleural mesothelioma. Support Care Cancer. 2013 Jul; 21(7):1879-1884. PMID: 23408016
  15. Cheng ASL, Li MS, Kang W, Cheng VY, Chou J-L, Lau SS, Go MY, Lee CC, Ling TK, Ng EK, Yu J, Huang TH, To KF, Chan MW, Sung JJY, Chan FKL. Helicobacter pylori Causes epigenetic dysregulation of foxd3 to promote gastric carcinogenesis. 2013 Jan; 144(1):122-133.e9. PMID: 23058321
  16. Kao SC, Vardy J, Harvie R, Chatfield M, van Zandwijk N, Clarke S, Pavlakis N. Health-related quality of life and inflammatory markers in malignant pleural mesothelioma. Support Care Cancer. 2013 Mar;21(3):697-705. PMID: 22936495
  17. Kao SC, Vardy J, Chatfield M, Corte P, Pavlakis N, Clarke C, van Zandwijk N, Clarke S. Validation of prognostic factors in malignant pleural mesothelioma: a retrospective analysis of data from patients seeking compensation from the New South Wales Dust Diseases Board. Clin Lung Cancer. 2013 Jan;14(1):70-7. PMID: 22658812 (Highly Cited Research in Clinical Lung Cancer awarded December 2016)
  18. Kao SCH, Lee K, Klebe S, Henderson D, McCaughan B, Vardy J, Clarke S, van Zandwijk N. Excision repair cross complementation group 1 and thymidylate synthase expression in patients with mesothelioma. Clin Lung Cancer. 2013 Mar;14(2):164-71. PMID: 23085037
  19. Linton A, Kao S, Vardy J, Clarke S, van Zandwijk N, Klebe S. Immunohistochemistry in the diagnosis of malignant pleural mesothelioma: Trends in Australia and a literature review. Asia Pac J Clin Oncol. 2013 Sep;9(3):273-79. PMID: 23167246
  20. Kao SC-H, Clarke S, Vardy J, Corte P, Clarke C, van Zandwijk N. Patterns of care for malignant pleural mesothelioma patients compensated by the Dust Diseases Board in New South Wales, Australia. Intern Med J. 2013 Apr;43(4):402-10.  PMID: 22909129

2012

  1. Linton A, van Zandwijk, Reid G, Clarke S, Cao C, Kao S. Inflammation in malignant mesothelioma – friend or foe? Ann Cardiothorac Surg. 2012 Nov;1(4):516-22. PMID: 23977546
  2. van Zandwijk N, Reid G, Linton A, Kao S. Radical surgery for malignant pleural mesothelioma: have we identified the appropriate selection tools? Ann Cardiothorac Surg. 2012 Nov;1(4):481-86.  PMID: 23977540
  3. Kao SC-H, Armstrong N, Condon B, Griggs K, McCaughan B, Maltby S, Wilson A, Henderson DW, Klebe S. Aquaporin 1 is an independent prognostic factor in pleural malignant mesothelioma. Cancer. 2012 Jun 1;118(11):2952-61. PMID: 22020536
  4. Linton A, Vardy J, Clarke S, van Zandwijk N. The ticking time-bomb of asbestos: Its insidious role in the development of malignant mesothelioma. Crit Rev Oncol Hematol. 2012 Nov;84(2):200-12. PMID: 22459593
  5. Kirschner MB, Cheng YY, Badrian B, Kao SC, Creaney J, Edelman JJB, Armstrong NJ, Vallely MP, Musk AW, Robinson BWS, McCaughan BC, Klebe S, Mutsaers SE, van Zandwijk N, Reid G. Increased circulating miR-625-3p: a potential biomarker for patients with malignant pleural mesothelioma. J Thorac Oncol. 2012 Jul;7(7):1184-91. PMID: 22617246
  6. Manegold C, van Zandwijk N, Szczesna A,  Zatloukal P, Au JSK, Blasinska-Morawiec M, Serwatowski P, Krzakowski M,  Jassem J,  Tan EH, Benner RJ, Ingrosso A, Meech SJ,  Readett D, Thatcher N. A phase III randomized study of gemcitabine and cisplatin with or without PF-3512676 (TLR9 agonist) as first-line treatment of advanced non-small-cell lung Ann Oncol. 2012 Jan;23(1):72–7.  PMID: 21464154
  7. Lasham A, Samuel W, Cao H, Patel R, Mehta R, Stern JL, Reid G, Woolley AG, Miller LD, Black MA, Shelling AN, Print CG, Braithwaite AW. YB-1, the E2F pathway, and regulation of tumor cell growth. J Natl Cancer Inst. 2012 Jan 18;104(2):133–46.  PMID: 22205655

2011

  1. Weder W, Stahel RA, Baas P, Dafni U, de Perrot M, McCaughan BC, Nakano T, Pass HI, Robinson BWS, Rusch VW, Sugarbaker DJ, van Zandwijk N. The MARS feasibility trial: conclusions not supported by data. Lancet Oncol. 2011 Nov;12(12):1093-4. PMID: 22041539
  2. Kao SC-H, Klebe S, Henderson DW, Reid G, Chatfield M, Armstrong NJ, Yan TD, Vardy J, Clarke S, van Zandwijk N, McCaughan B. Low calretinin expression and high neutrophil-to-lymphocyte ratio are poor prognostic factors in patients with malignant mesothelioma undergoing extrapleural pneumonectomy. J Thorac Oncol. 2011 Nov;6(11):1923-9. PMID: 22011651
  3. Reid G, Kirschner MB, van Zandwijk N. Circulating microRNAs: association with disease and potential use as biomarkers. Crit Rev Oncol Hematol. 2011 Nov;80(2):193–208. PMID: 21145252
  4. Kirschner MB, Kao SC, Edelman JJ, Armstrong NJ, Vallely MP, van Zandwijk N, Reid G. Haemolysis during sample preparation alters microRNA content of plasma. PLoS One. 2011;6(9):e24145. PMID: 21909417
  5. Kao SC-H, Griggs K, Lee K, Armstrong N, Clarke S, Vardy J, van Zandwijk N, Burn J, McCaughan BC, Henderson DW, Klebe S. Validation of a minimal panel of antibodies for the diagnosis of malignant pleural mesothelioma. Pathology. 2011 Jun;43(4):313-7. PMID: 21532523
  6. Herbert M, Coppieters N , Lasham  A, Cao H, Reid G. The importance of RT-qPCR primer design for the detection of siRNA-mediated mRNA silencing. BMC Res Notes. 2011 May 25;4:148.  PMID: 21612654
  7. Heigener DF, Wu YL, van Zandwijk N, Mali P, Horwood K, Reck M. Second-line erlotinib in patients with advanced non-small-cell lung cancer: Subgroup analyses from the TRUST study. Lung Cancer. 2011 Nov;74(2):274-9. PMID: 21439671
  8. Kao SC-H, Lee K, Armstrong NJ, Clarke S, Vardy J, van Zandwijk N, Reid G, Burn J, McCaughan BC, Henderson DW, Klebe S. Validation of tissue microarray technology in malignant pleural mesothelioma. Pathology. 2011 Feb;43(2):128-32. PMID: 21233673
  9. Kao SC-H, Reid G, van Zandwijk N, Henderson DW, Klebe S. Molecular biomarkers in malignant mesothelioma - state of the art. Pathology. 2011 Apr;43(3):201-12. PMID: 21436629
  10. Kao SC-H, Yan TD, Lee K, Burn J, Henderson DW, Klebe S, Kennedy C, Vardy J, Clarke S, van Zandwijk N, McCaughan BC. Accuracy of diagnostic biopsy for the histological subtype of malignant pleural mesothelioma. J Thorac Oncol. 2011 Mar;6(3):602-5. PMID: 21266919
  11. Li Y, Revalde L, Reid G, Paxton JW. Modulatory effects of curcumin on multi-drug resistance associated protein 5 in pancreatic cancer cells. Cancer Chemother Pharmacol. 2011 Sep;68(3):603-10.  PMID: 21116627
  12. Kao SCH, Butow P, Bray V, Clarke SJ, Vardy J. Patient and oncologist estimates of survival in advanced cancer patients. Psychooncology. 2011 Feb;20(2):213-8.  PMID: 20878829

2010

  1. Reck M, van Zandwijk N, Gridelli C, Baliko Z, Rischin D, Allan S, Krzakowski M, Heigener D. Erlotinib in advanced non-small cell lung cancer: efficacy and safety findings of the global phase IV Tarceva Lung Cancer Survival Treatment study. J Thorac Oncol. 2010 Oct;5(10):1616-22. PMID: 20736854
  2. Li Y, Revalde JL, Reid G, Paxton JW. Interactions of dietary phytochemicals with ABC transporters: possible implications for drug disposition and multidrug resistance in cancer. Drug Metab Rev. 2010 Nov;42(4):590-611. PMID: 20433315
  3. Lasham A, Herbert M, Coppieters 't Wallant N, Patel R, Feng S, Eszes M, Cao H, Reid G. A rapid and sensitive method to detect siRNA-mediated mRNA cleavage in vivo using 5' RACE and a molecular beacon probe. Nucleic Acids Res. 2010 Jan;38(3):e19. PMID: 19942683
  4. Kappers I, van Sandick JW, Burgers SA, Belderbos JSA, van Zandwijk N, Klomp HM. Surgery after induction chemotherapy in stage IIIA-N2 non-small cell lung cancer: why pneumonectomy should be avoided. Lung Cancer. 2010 May;68(2):222-7. PMID: 19664843
  5. Kao SC-H, Reid G, Lee K, Vardy J, Clarke S, van Zandwijk N. Malignant Mesothelioma. Intern Med J. [Review]. 2010 Nov;40(11):742–50. PMID: 20298508
  6. Kao SC-H, Phan VH, Clarke SJ. Predictive markers for haematological toxicity of pemetrexed. Curr Drug Targets. 2010 Jan;11(1):48-57. PMID: 19839928
  7. Kao SC-H, Pavlakis N, Harvie R, Vardy JL, Boyer MJ, van Zandwijk N, Clarke SJ. High blood neutrophil-to-lymphocyte ratio is an indicator of poor prognosis in malignant mesothelioma patients undergoing systemic therapy. Clin Cancer Res. 2010 Dec 1; 16(23):5805-13. PMID: 20956618
  8. Kao SC-H, McCaughan B, Muljono A, Boyer M. A pathological complete response in malignant pleural mesothelioma after combination chemotherapy with Carboplatin and pemetrexed. J Thorac Oncol. 2010 Mar;5(3):405-6. PMID: 20186029
  9. Cheng YY, Chau D, Chan T, Gill H, Liang R, Kwong YL, Tse E. Absence of NPM1 promoter hypermethylation in human myelodysplastic syndrome. J Clin Pathol. 2010 Nov; 63(11):1008-11. PMID: 20924036
  10. Smit EF, Groen HJM, van Zandwijk N. Reply to L. H. de Lima Araújo et al. J Clin Oncol. 2010 Jan 10;28(2):e26.
  11. Kappers I, Vollebergh MA, van Tinteren H, Korse CM, Nieuwenhuis LL, Bonfrer JMG, Klomp HM, van Zandwijk N, van den Heuvel MM. Soluble epidermal growth factor receptor (sEGFR) and carcinoembryonic antigen (CEA) concentration in patients with non-small cell lung cancer: correlation with survival after erlotinib and gefitinib treatment. Ecancermedicalscience. 2010;4:178.  PMID: 22276032

2009

  1. van Zandwijk N. Individualization of treatment in non-small cell lung cancer. F1000 Med Rep. 2009 Mar 24;1:24. PMID: 20948757
  2. Van den Heuvel MM, Burgers SA, van Zandwijk N. Immunotherapy in non-small-cell lung carcinoma: from inflammation to vaccination. Clin Lung Cancer. 2009 Mar;10(2):99-105. PMID: 19362952
  3. Smit EF, Burgers SA, Biesma B, Smit HJM, Eppinga P, Dingemans A-MC, Joerger M, Schellens JH, Vincent A, van Zandwijk N, Groen HJM. Randomized phase II and pharmacogenetic study of pemetrexed compared with pemetrexed plus carboplatin in pretreated patients with advanced non-small-cell lung cancer. J Clin Oncol. 2009 Apr 20;27(12):2038-45. PMID: 19307503
  4. Roepman P, Jassem J, Smit EF, Muley T, Niklinski J, van de Velde T, Witteveen AT, Rzyman W, Floore A, Burgers S, Giaccone G, Meister M, Dienemann H, Skrzypski M, Kozlowski M, Mooi WJ, van Zandwijk N. An immune response enriched 72-gene prognostic profile for early-stage non-small-cell lung cancer. Clin Cancer Res. 2009 Jan 1;15(1):284-90. PMID: 19118056
  5. Reid G, Coppieters 't Wallant N, Patel R, Antonic A, Saxon-Aliifaalogo F, Cao H, Webster G, James D Watson JD. Potent subunit-specific effects on cell growth and drug sensitivity from optimised siRNA-mediated silencing of ribonucleotide reductase. J RNAi Gene Silencing. 2009 Mar 9;5(1):321-30.  PMID:19771229
  6. Patel R, Coppieters 't Wallant N, Herbert MH, White D, Murison JG, Reid G. The potency of siRNA-mediated growth inhibition following silencing of essential genes is dependent on siRNA design and varies with target sequence. Oligonucleotides. 2009 Dec;19(4):317-28. PMID: 19943803
  7. Kappers I, van Sandick JW, Burgers JA, Belderbos JSA, Wouters MW, van Zandwijk N, Klomp HM. Results of combined modality treatment in patients with non-small-cell lung cancer of the superior sulcus and the rationale for surgical resection. Eur J Cardiothorac Surg. 2009 Oct;36(4):741-6. PMID: 19699647
  8. Kao S, Mahon K, Lin B, Rutland J, Pawsey C, McCaughan B, Beale P. Pleural well-differentiated papillary mesothelioma: a case report. J Thorac Oncol. 2009 Jul;4(7):920-2. PMID: 19550246
  9. Geurts TW, van Velthuysen MLF, Broekman F, van Huysduynen TH, van den Brekel MWM, van Zandwijk N, van Tinteren H, Nederlof P, Balm AJM, Brakenhoff RH. Differential diagnosis of pulmonary carcinoma following head and neck cancer by genetic analysis. Clin Cancer Res. 2009 Feb 1;15(3):980-5. PMID: 19188169
  10. Geurts TW, Balm AJM, van Velthuysen M-LF, van Tinteren H, Burgers JA, van Zandwijk N, Klomp HM. Survival after surgical resection of pulmonary metastases and second primary squamous cell lung carcinomas in head and neck cancer. Head Neck. 2009 Feb;31(2):220-6.  PMID: 18972427

Book Chapters

2017

  1. Gulati S, Mulshine JL, van Zandwijk N. Section 1: Lung Cancer Control and Epidemiology, 9 - Chemoprevention of Lung Cancer and Management of Early Lung Cancer. In: Pass HI, Ball D, Scagliotti GV, editors. IASLC Thoracic Oncology (Second Edition): Elsevier Inc.; 2017. p. 69-81.e5.  ISBN 978-0-323-52357-8

2016

  1. Soeberg M, van Zandwijk N. Chapter 9: Asbestos and malignant pleural mesothelioma. In: Mineo TC (ed) Malignant pleural mesothelioma: Present status and future direction. Benthem Science Publishers; 2016 (eBook). Chapter 9; p115-128. eISBN 978-1-68108-193-9. ISBN 978-1-68108-194-6 http://ebooks.benthamscience.com/book/9781681081939/

2015

  1. Maher SG, Bibby BAS, Moody HL, Reid G. MicroRNAs and Cancer. In: Gray SG, Editor, Epigenetic Cancer Therapy, Translational Epigenetics Series. Elsevier; 2015. Chapter 4; p67-90.  ISBN 978-0-12-800206-3
  2. Wright CM. Long noncoding RNAs and cancer. In: Gray SG, Editor, Epigenetic Cancer Therapy, Translational Epigenetics Series. Elsevier; 2015. Chapter 5; p91-114. ISBN 978-0-12-800206-3

2014

  1. Gulati S, Mulshine JL, van Zandwijk N. Chapter 9: Chemoprevention of lung cancer and management of early lung cancer. In: Pass HI (ex. editor), Ball D, Scagliotti GV (eds.) The IASLC Multidisciplinary Approach to Thoracic Oncology.  Aurora, CO: International Association for the Study of Lung Cancer. 2014: 105-123

2010

  1. van Zandwijk N. Occurrence and chemoprevention of lung cancer. In: Manegold C, editor. Non-small cell lung cancer treatment. Beijing: People's Medical Publishing House; 2010. p. 117-33.
  2. van Zandwijk N. Lung Carcinogenesis and Chemoprevention. In Manegold C. Non-Small Cell Lung cancer Treatment. 2nd Ed. Uni-Med Verlag AG. Bremen 2010; 15:165-176
  3. Khuri F, van Zandwijk N. Chapter 21: Molecular carcinogenesis and chemoprevention of lung cancer. In: Pass HI, Carbone DP, Johnson DH, Minna JD, Scagliotti GV, Turrisi III AT (eds.) Principals and Practice of Lung Cancer: The official reference text of the IASLC. 4th Ed. Lippincott, Williams & Wilkens, Philadelphia, USA. 2010: 275-283

2009

  1. van Zandwijk N. Lung cancer: oncogenesis and prevention. In: Thoracic Malignancies. Spiro SG, Huber RM, Janes SM, editors. The European Respiratory Monograph, Plymouth, UK: European Respiratory Society Journals; 2009: 1-14

Guidelines

2013

  1. Guidelines for the Diagnosis and Treatment of Malignant Pleural Mesothelioma

Asbestos Diseases Research Institute, July 2013

For more information on the Guidelines for the Diagnosis and Treatment of Malignant Pleural Mesothelioma, click here.